
CVRx (NASDAQ:CVRX) reported first-quarter 2026 revenue of $14.8 million, up 20% from the prior-year period, as U.S. growth in its Barostim heart failure business helped the company exceed the high end of its guidance range, executives said on the company’s earnings call.
President and Chief Executive Officer Kevin Hykes said the quarter showed “early evidence” that investments made during 2025 are beginning to translate into results. Those efforts included strengthening the sales organization, refining the company’s go-to-market strategy, advancing reimbursement initiatives and securing approval for the BENEFIT-HF clinical trial.